JUL 10, 2018 10:30 PM PDT

The ALFRED Analysis for Cancer Predisposition Genes

A group of researchers in Spain methodically evaluated exome data from 10,000 tumors in an attempt to identify cancer predisposition genes as well as verify their statistical method.  They created a statistical method called ALFRED, which stands for allelic loss featuring rare damaging.  They used this method to evaluate Alfred Knudson’s classic “two hit” postulation which originated in 1971.  The article was published July 4, 2018 in Nature Communications.

Knudson was a geneticist researching retinoblastoma and his interest focused on the loss of function mechanism based on the knowledge that most tumor suppressor genes are recessive in nature.  This is what led him to propose the “two hit” hypothesis as a mechanism for the de novo development of cancer. 

The ALFRED model utilizes a principal component analysis to cluster common variants in cancer patients.  Then using two different test types, they quantify rare damaging germline variants with loss of heterozygosity events (termed allelic imbalance) compared to matched non-tumor samples from each patient which leads to an ALFRED P-value.  ALFRED was applied to 10,043 tumor exomes which had sequencing data as part of The Cancer Genome Atlas project. 

After evaluating the data against previously known cancer predisposition genes from recent literature reviews and the Cancer Gene Census, the group determined that these showed increased numbers of rare damaging germline variants with high frequency of allelic imbalance.  They also evaluated somatic cancer genes for germline risk variants; their findings indicate that there are a few genes that are affected by somatic changes but may also further cancer development because of rare germline variations.

The research points to potential new germline cancer predisposition variants including NSD1, MYH1, NOP56, PRPF8, INO80, ANK2, and ATM.

More significant research is needed to explore the use of a statistical method like ALFRED to further classify these cancer predisposition genes, in addition to clinical tumor testing research to identify these genes in patients with specific cancers.

Sources: Nature Communications, Nature Education, The Cancer Genome Atlas,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
AUG 14, 2018
Cancer
AUG 14, 2018
Can Zika Virus Help Neuroblastoma Patients?
Researchers in Florida published the potential for Zika virus to help in the treatment of Neuroblastoma in patients of all ages....
SEP 05, 2018
Videos
SEP 05, 2018
Why Glioblastoma Is So Deadly
Senator John McCain passed away recently after battling brain cancer. Most forms of brain cancer are aggressive and difficult to treat because medications...
SEP 26, 2018
Cancer
SEP 26, 2018
Rare Cancer the Focus of Mesothelioma Awareness Day
More than 2,500 Americans are diagnosed with mesothelioma cancer each year. The cancer is rare but very serious - most patients diagnosed with the disease live just a short 12 to 21 months....
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Making Cancer Disappear?
Neuroblastoma is one of the most common childhood cancers and the leading cause of cancer deaths among pediatric patients younger than 5. The cancer is fre...
JAN 07, 2019
Microbiology
JAN 07, 2019
New Insight Into HPV Opens up Potential Treatment Avenues
Human papillomavirus (HPV) causes nearly every case of cervical cancer....
JAN 16, 2019
Cell & Molecular Biology
JAN 16, 2019
Molecule Can Reduce the Growth & Spread of Breast Cancer
A protein called Nischarin can help stop breast cancer from growing and metastasizing....
Loading Comments...